• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Ramsay Health Care (ASX:RHC) Could Be 7% Overvalued Following Q1 Earnings Update

    Simply Wall St·11/09/2026 19:39:52
    Listen to the news

    Ramsay Health Care earnings and transformation program back in focus

    Ramsay Health Care (ASX:RHC) is back on investor watch after its Q1 2027 results on 5 November and a follow up earnings call on 6 November highlighted progress in its Australian hospital transformation program.

    Ramsay Health Care shares closed at A$55.49, with the 90 day share price return of 23.12% and year to date share price return of 60.42% pointing to strong momentum building around the transformation story. The 1 year total shareholder return of 84.68% contrasts with a weaker 5 year total shareholder return that declined 11.78%, reminding investors that the recent recovery follows a much tougher longer stretch.

    Scan how Ramsay Health Care fits alongside other hospital and healthcare operators showing strong fundamentals with the hand picked list of solid balance sheet and fundamentals (12 results).

    That kind of rebound in Ramsay Health Care after a tougher five year stretch poses a practical choice. Do you step in after this run, or wait for a cleaner entry as the valuation case stacks up next?

    Most Popular Narrative: 6.7% Overvalued

    On the Simply Wall St analyst consensus Narrative, Ramsay Health Care screens as slightly expensive, with a fair value of A$52.02 against the last close at A$55.49. That view anchors on how much of the Australian hospital transformation is already reflected in the share price.

    The multiyear Australian hospital transformation program, which has already coincided with 11.2% underlying EBIT growth and 30 bps margin expansion in FY26 for Ramsay Australia, continues to target higher acuity case mix, better theatre utilisation and procurement savings that can support further EBIT and net margin improvement.

    See why 44 investors see Ramsay Health Care as 7% overvalued.

    In that analyst consensus Narrative on Simply Wall St, the fair value is built off A$21.0b in 2029 revenue, A$551.7m in earnings and a 27.2x future P/E, discounted back at 7.76%. With Ramsay Health Care now trading about 6.7% above that A$52.02 mark, the numbers frame the current price as already baking in meaningful execution on margins, cash generation and capital discipline.

    Result: Fair Value of A$52.02 (OVERVALUED)

    Still, if wage inflation or regulatory pressure in key regions like Australia and France bites harder than funding and indexation, the Ramsay Health Care execution story could quickly look stretched.

    Find out about the key risks to this Ramsay Health Care narrative.

    Next Steps

    If the Ramsay Health Care story appears evenly poised between promise and pressure, consider reviewing it while the data is current and weigh it up yourself with 2 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond Ramsay Health Care?

    Ramsay Health Care might be front of mind today, but your next opportunity could sit in a completely different corner of the market if you know where to look.